5-Azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: Role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand

Blood

Volumn 119, Issue 18, 2012, Pages 4242-4252

  Ghanim, Viviane ^a   Herrmann, Harald ^b   Heller, Gerwin ^a   Peter, Barbara ^b   Hadzijusufovic, Emir ^a,c   Blatt, Katharina ^a   Schuch, Karina ^d   Cerny Reiterer, Sabine ^a,b   Mirkina, Irina ^b   Karlic, Heidrun ^b,e   Pickl, Winfried F ^d   Zöchbauer Müller, Sabine ^a   Valent, Peter ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e HANUSCH HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BETA ACTIN; CASPASE 3; CASPASE 8; FAS ANTIGEN; FAS LIGAND; PROTEIN P15; PROTEIN P16; PROTEIN P21; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DEMETHYLATION; DRUG EFFECT; DRUG POTENTIATION; EPIGENETICS; FAS GENE; GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; MAST CELL; MAST CELL LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SYSTEMIC MASTOCYTOSIS;

EID: 84860827822     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-382770     Document Type: Article

References (49)

1. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003;122(5):695-717. (Pubitemid 37100296)
2. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med. 2004;55:419-432. (Pubitemid 38316735)
3. Valent P, Horny H-P, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Conference Report of "Year 2000 Working Conference on Mastocytosis". Leuk Res. 2001;25(7):603-25. (Pubitemid 32506768)
4. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6):435-453. (Pubitemid 46817344)
5. Horny HP, Akin C, Metcalfe DD, et al. Mastocytosis (Mast cell disease). World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. In: Swerdlow SH, Campo E, Harris LH, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JM, eds. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:2:54-263.
6. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92(23):10560-10564.
7. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996;12(3):312-314. (Pubitemid 26080092)
8. Fritsche-Polanz R, Jordan JH, Feix A, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001;113(2):357-364. (Pubitemid 32523138)
9. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23): 5727-5736.
10. Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124(3):514-521.
11. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res. 2004;28(3):249-257. (Pubitemid 37550059)
12. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102(13):4270-4276. (Pubitemid 37494083)
13. Gotlib J, Berubé C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106(8):2865-2870. (Pubitemid 41510766)
14. Purtill D, Cooney J, Sinniah R, et al. Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol. 2008;80(5):456-458. (Pubitemid 351503111)
15. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosomenegative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008;14(12):3906-3915.
16. Valent P, Ghannadan M, Akin C, et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic MCs and evaluation of arising treatment concepts. Eur J Clin Invest. 2004;34(2):41-52. (Pubitemid 39331488)
17. Pardanani A, Akin C, Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol. 2006; 19(3):595-615. (Pubitemid 43869476)
18. Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007;13(6):1634-1637.
19. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148-1159.
20. Sharma S, Kelly TK, Jones PA. Epigenetics in Cancer. Carcinogenesis. 2010;31(1):27-36.
21. Silverman LR, Mufti GJ. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol. 2005;2(1):12-23.
22. Müller CI, Rüter B, Koeffler HP, Lübbert M. DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. Curr Pharm Biotechnol. 2006;7(5):315-321. (Pubitemid 44524413)
23. Kuendgen A, Lübbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol. 2008;87(8):601-611.
24. Kantarjian HM, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007;109(6):1133-1137. (Pubitemid 46435392)
25. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
26. Wijermans PW, Rüter B, Baer MR, Slack JL, Saba HI, Lübbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2008;32(4): 587-591. (Pubitemid 351248959)
27. Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies. Blood. 2010; 116(19):3735-3742.
28. Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol. 2002; 127(2):140-142. (Pubitemid 34264203)
29. Mirkina I, Schweighoffer T, Kricek F. Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab. Immunol Lett. 2007;109(2):120-128. (Pubitemid 46452748)
30. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988;12(4):345-355.
31. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human MCs bearing wild-type or mutated c-kit. Exp Hematol. 2003;31(8):686-692. (Pubitemid 36945381)
32. Gleixner K, Mayerhofer M, Aichberger K, et al. PKC412 inhibits in vitro growth of neoplastic human MCs expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects. Blood. 2006;107(2):752-759. (Pubitemid 43076402)
33. Kondo R, Gleixner KV, Mayerhofer M, et al. Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic MCs. Blood. 2007;110(2):661-669. (Pubitemid 47105405)
34. Gleixner KV, Ferenc V, Peter B, et al. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res. 2010; 70(4):1513-1523.
35. Sambrook J, Fritsch EF, Maniatis T. Isolation of DNA from mammalian cells: Protocol I. In: Molecular Cloning: A Laboratory Manual. Vol 2. New York, NY: Cold Spring Harbor Laboratory Press; 1989:9-16.
36. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821-9826. (Pubitemid 26296693)
37. Heller G, Weinzierl M, Noll C, et al. Genome-wide microRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res. 2012;18(6):1619-1629.
38. Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23(6):1019-1028.
39. Schnekenburger M, Grandjenette C, Ghelfi J, et al. Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. Biochem Pharmacol. 2011;81(3):364-378.
40. Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One. 2011;6(3):e17388.
41. Petak I, Danam RP, Tillman DM, et al. Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ. 2003; 10(2):211-217. (Pubitemid 36553463)
42. Lavelle D, DeSimone J, Hankewych M, Kousnetzova T, Chen YH. decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leuk Res. 2003;27(11):999-1007. (Pubitemid 36809073)
43. Hirata H, Hinoda Y, Nakajima K, et al. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer. 2011; 128(8):1793-1803.
44. Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS. 5-Aza-2′-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res. 2010; 34(3):364-372.
45. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 2010;5(2):e9001.
46. Ruiz-Magaña MJ, Rodríguez-Vargas JM, Morales JC, Saldivia MA, Schulze-Osthoff K, Ruiz-Ruiz C. The DNA-methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells. Int J Cancer. 2012;130(5):1195-1207.
47. Stresemann C, Bokelmann I, Mahlknecht U, Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther. 2008;7(9):2998-3005.
48. Giraud S, Bessette B, Boda C, et al. In vitro apoptotic induction of human glioblastoma cells by Fas ligand plus etoposide and in vivo antitumour activity of combined drugs in xenografted nude rats. Int J Oncol. 2007;30(1):273-281.
49. Liu Z, Liu R, Qiu J, et al. Combination of human Fas (CD95/Apo-1) ligand with adriamycin significantly enhances the efficacy of antitumor response. Cell Mol Immunol. 2009;6(3):167-174.